ArticleSurgical endoscopy2025
Short-term outcomes of robot-assisted transcervical esophagectomy for thoracic esophageal carcinoma.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Right-first bilateral transcervical and transhiatal single-port robotic esophagectomy using the da Vinci SP system.Esophagus : official journal of the Japan Esophageal Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimally invasive robot-assisted transcervical esophagectomy (TCE) has emerged as a novel technique for thoracic esophagectomy in patients with thoracic esophageal carcinoma, with sporadic reports highlighting its feasibility. However, its short-term surgical outcomes and safety profile in a well-defined series with a substantial number of cases remain unclear. This study aims to address this knowledge gap by systematically evaluating the feasibility and safety of this approach.
methodsFifty patients undergoing robot-assisted TCE between 2023 and 2024 were included. At our institution, robot-assisted TCE is reserved for patients with previous thoracic surgery, poor performance status, or other conditions contraindicating thoracic approaches. This procedure employed bilateral cervical approaches with continuous nerve-integrated monitoring in all cases. Robot-assisted TCE was performed using the da Vinci Xi system, with dissection and lymphadenectomy of the thoracic esophageal regions, including the bilateral recurrent laryngeal nerve lymph nodes.
resultsAll patients successfully underwent robot-assisted TCE with no intraoperative adverse events. The mean patient age was 73.8 years, and the male-to-female ratio was 43:7. Clinical staging was I/II/III/IV: 19/6/20/5, with 58% of patients receiving neoadjuvant chemotherapy. More than 80% had significant systemic or pulmonary comorbidities. All robot-assisted TCE procedures, including bilateral cervical dissection, were performed without intraoperative complications. Postoperative complications included recurrent laryngeal nerve paralysis (12.0%, Clavien-Dindo Grade ≥ 1) and pneumonia (6.0%, Grade ≥ 2).
conclusionsRobot-assisted TCE is a relatively safe and feasible technique. The transhiatal robotic approach allows for precise mediastinal lymphadenectomy. Short-term outcomes suggest acceptable rates of recurrent laryngeal nerve paralysis and pulmonary complications. Further research will focus on improving reproducibility in challenging cases and evaluating mid-term outcomes.
Indexed as
Identifiers
40676301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.